Discover ZEISS MyoActive, its M.O.V.E. technology, clinical results and benefits for childhood myopia. Coming soon to Malaya Optical Malaysia.
ZEISS MyoActive Malaysia: A New Approach to Childhood Myopia Management With M.O.V.E. Technology
ZEISS MyoActive introduces Dynamic Signal Theory and a new spectacle-lens design intended to help slow myopia progression in children. Discover how it works, what the clinical research shows and what Malaysian parents should know.
Your child’s spectacle prescription was −1.00D last year. At their latest eye examination, it has increased to −2.00D.
For many Malaysian parents, this raises an important question: Is there a way to slow my child’s increasing short-sightedness rather than simply replacing their glasses every year?
Today, myopia management offers several approaches designed to help slow the progression of childhood short-sightedness.
One of the latest developments is ZEISS MyoActive, a new-generation myopia-management spectacle lens officially introduced by ZEISS on 1 October 2026.
Featuring patented M.O.V.E. technology (Micro Optical Variable Elements), MyoActive uses a specialised optical design based on Dynamic Signal Theory.
ZEISS reports promising one-year clinical findings, including 0.60 dioptres (D) less myopia progression and 0.22 millimetres (mm) less axial elongation compared with conventional single-vision spectacles.
ZEISS MyoActive is coming soon to Malaya Optical Malaysia, with planned availability at our four branches in Kuala Lumpur, Petaling Jaya, Subang Jaya and Puchong.
Here is what parents should understand about the technology, research, benefits and importance of ongoing eye-growth monitoring.
What Is ZEISS MyoActive?
ZEISS MyoActive is a specialised spectacle lens designed to correct childhood myopia while providing optical signals intended to help slow its progression.
Unlike ordinary single-vision spectacles, which primarily correct blurred distance vision, MyoActive incorporates microscopic optical structures within the lens.
These structures create varying myopic-defocus signals as a child moves their eyes through different parts of the lens.
The technology is called ZEISS M.O.V.E. — Micro Optical Variable Elements.
MyoActive is worn like everyday spectacles. Children do not need to insert contact lenses, sleep with lenses on their eyes or follow a contact lens cleaning routine.
This may make spectacle-based myopia management particularly appealing to families whose children are newly diagnosed with short-sightedness.
However, MyoActive does not cure myopia or guarantee that progression will stop. Its purpose is to help slow progression, with individual outcomes varying between children.
Why Is Childhood Myopia Progression a Concern?
Myopia, commonly called short-sightedness, occurs when distant light focuses in front of the retina rather than directly on it.
In many children, this is associated with excessive elongation of the eyeball.
As the eye grows longer, the child’s spectacle prescription may become increasingly negative.
For example, a child might progress from −1.00D to −2.00D and eventually −3.00D.
Progression varies. Some children experience relatively small changes, while others develop stronger prescriptions over a short period.
Higher levels of myopia are associated with increased lifetime risks of certain eye conditions, including myopic maculopathy, retinal detachment and glaucoma.
This is why modern myopia management focuses on more than clear vision.
The goal is to help slow excessive eye growth during childhood, when myopia commonly progresses.
Correcting Myopia vs Managing Myopia
Conventional single-vision spectacles correct the child’s existing refractive error.
Myopia-management spectacles aim to provide clear vision while delivering additional optical signals intended to slow progression.
ZEISS MyoActive belongs to this second category.
What Is ZEISS M.O.V.E. Technology?
M.O.V.E. stands for Micro Optical Variable Elements.
It is the patented optical technology used in ZEISS MyoActive.
The lens incorporates microscopic optical treatment structures arranged in a deliberately non-repetitive pattern.
As the child moves their eyes, different parts of the lens create varying optical-defocus signals.
ZEISS designed this approach to investigate whether changing optical stimulation can help maintain the visual system’s response to myopic defocus.
How Is MyoActive Designed?
According to ZEISS’s technical information, the lens incorporates:
- A central clear zone for the child’s distance prescription
- A surrounding treatment area containing micro-optical structures
- A non-repetitive arrangement of treatment elements
- Optical elements designed to create varying myopic-defocus signals
- ZEISS ClearFocus optimisation to support vision through the lens
The treatment structures have optical powers that differ from the child’s prescribed correction.
These additional powers are part of the myopia-management design, not a replacement for the child’s normal spectacle prescription.
How Does Myopic Defocus Work?
Ordinary spectacle lenses focus light to correct blurred vision.
Specialised myopia-management lenses are designed to create additional optical signals, including myopic defocus, alongside the main prescription.
Myopic defocus refers to light focusing in front of the retina.
Researchers believe appropriately designed myopic-defocus signals can influence eye-growth regulation and help slow excessive axial elongation.
Different manufacturers use different optical structures to produce these signals.
ZEISS MyoActive introduces a distinctive approach by making the signals spatially variable.
Understanding Dynamic Signal Theory
Dynamic Signal Theory is central to the MyoActive design.
Many myopia-management spectacle lenses use regular optical treatment patterns.
ZEISS is investigating whether the visual system may gradually adapt to repeated optical signals.
What Is Visual Adaptation?
Our visual system constantly adjusts to the information it receives.
For example, when we enter a brightly lit room, our eyes gradually adapt to the new lighting conditions.
ZEISS proposes that a similar adaptation process could influence the response to repetitive optical-defocus signals.
If the visual system becomes accustomed to a particular treatment pattern, the response to that pattern might change.
How MyoActive Uses Dynamic Signals
MyoActive uses non-repetitive micro-optical structures to create changing defocus signals as the eyes move naturally.
Rather than presenting an identical optical pattern throughout the treatment area, it introduces variation.
ZEISS designed this approach with the intention of reducing adaptation and maintaining responsiveness to myopic-defocus signals.
In simple terms, MyoActive is designed to vary the optical treatment signal as the child looks around.
What Has Not Yet Been Proven?
The theory is scientifically interesting, but it is important to distinguish the proposed mechanism from the clinical outcomes.
A clinical trial can demonstrate that children wearing MyoActive experience slower myopia progression than children wearing ordinary spectacles.
However, that finding alone does not prove that reduced neural adaptation is the specific biological reason for the improvement.
Further research is needed to clarify the mechanisms behind Dynamic Signal Theory and how they influence long-term outcomes.
For parents, the most important question remains whether the lens helps slow progression and whether their child responds well to treatment.
What Does the ZEISS MyoActive Clinical Research Show?
ZEISS presented initial MyoActive clinical findings at the 2026 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.
The research is part of an ongoing prospective, multicentre, double-masked, randomized controlled trial registered as NCT06563700.
How Was the Study Conducted?
The overall trial enrolled 342 Chinese children aged 7–13 years.
Participants had starting spherical equivalent prescriptions between approximately −0.75D and −5.00D.
Children were assigned to six groups:
- Five experimental myopia-management spectacle-lens designs
- One conventional single-vision spectacle-lens control group
One of the experimental designs was subsequently identified as ZEISS MyoActive.
For the one-year findings announced by ZEISS, the relevant comparison involved 56 MyoActive wearers and 56 single-vision wearers.
Researchers evaluated two important outcomes: refractive progression and axial elongation.
What Is Refractive Progression?
Refractive progression measures how much a child’s prescription changes over time.
It is usually expressed in dioptres (D).
A larger negative change indicates increasing short-sightedness.
What Is Axial Elongation?
Axial elongation measures how much the eye grows from front to back.
It is expressed in millimetres.
Because excessive eye elongation is closely associated with myopia progression, axial length is an important measurement in myopia-management research.
ZEISS MyoActive Six-Month Clinical Results
At six months, ZEISS reported that children wearing MyoActive experienced average changes of:
−0.13D in refractive error
and
0.02 mm in axial length.
Compared with children wearing conventional single-vision spectacles, the MyoActive group experienced:
| Clinical measurement | Difference compared with single-vision spectacles |
|---|---|
| Refractive progression | 0.38D less progression |
| Axial elongation | 0.15 mm less eye growth |
| Observation period | Six months |
These are average differences between study groups.
They do not mean that every child experienced the same result.
The findings nevertheless suggest that the MyoActive design can help slow both prescription progression and axial elongation during the observed period.
ZEISS MyoActive One-Year Clinical Results
On 1 October 2026, ZEISS announced updated one-year findings from the ongoing clinical trial.
The company reported:
| Clinical outcome | One-year result reported by ZEISS |
|---|---|
| Difference in myopia progression compared with single vision | 0.60D less progression |
| Difference in axial elongation compared with single vision | 0.22 mm less eye growth |
| Average refractive progression among MyoActive wearers | −0.23D over one year |
| Children adapting within one week | Approximately 98% |
What Does 0.60D Less Myopia Progression Mean?
Imagine two groups of children with similar starting prescriptions.
One group wears ordinary single-vision spectacles.
The other wears ZEISS MyoActive.
After one year, the MyoActive group experiences an average prescription change that is 0.60D smaller than the single-vision group.
This does not mean that MyoActive reverses an existing prescription by 0.60D.
It also does not mean that every child experiences the same benefit.
The figure describes the difference in average progression between the two groups.
What Does 0.22 mm Less Axial Elongation Mean?
Axial length measures the length of the eye from front to back.
A reduction of 0.22 mm in axial elongation means the MyoActive group experienced less average eye growth than the single-vision comparison group.
This is clinically relevant because myopia management is concerned with excessive eye elongation, not only spectacle prescription.
Did MyoActive Stop Myopia Progression?
ZEISS reported an average annual refractive change of approximately −0.23D among MyoActive wearers.
This is smaller than the 0.25D increment commonly used during subjective spectacle refraction.
ZEISS therefore described the average change as below a threshold of clinical relevance.
However, a small average change across a study group does not mean every child’s myopia stopped progressing.
Some children may respond strongly, while others may continue to experience progression.
How Strong Is the Clinical Evidence?
The MyoActive findings are promising, but they should be interpreted carefully.
Strengths of the Research
The study uses a randomized, double-masked, multicentre design.
It includes a conventional single-vision comparison group.
Researchers measure both refractive progression and axial length.
The broader trial also evaluates several different optical treatment designs.
Important Limitations
The trial participants were Chinese children aged 7–13 years within a defined prescription range.
Results may differ in other populations, ages and clinical circumstances.
The trial is ongoing, so longer-term results remain important.
The one-year findings announced in October 2026 were described by ZEISS as data on file.
They should not be presented as a fully independently peer-reviewed one-year publication unless such a publication becomes available.
The precise contribution of reduced visual adaptation to the observed treatment effect also remains under investigation.
The current findings support MyoActive as a promising myopia-management spectacle lens, but they do not establish that it is superior to every competing lens technology.
Is ZEISS MyoActive Comfortable for Children?
A myopia-management spectacle lens must provide more than an optical treatment signal.
Children also need comfortable vision during school, reading, outdoor activities and everyday routines.
ZEISS reported that approximately 98% of MyoActive study participants adapted to the lenses within one week.
The company also reported favourable assessments of visual clarity at different viewing distances.
However, peripheral letter recognition was slightly reduced under certain testing conditions.
This is worth acknowledging because specialised myopia-management lenses contain optical treatment zones that differ from ordinary single-vision spectacles.
Some children may need time to become accustomed to the lens design.
Professional fitting and appropriate adaptation advice are important.
Parents should inform their optometrist if their child experiences persistent discomfort or difficulty with everyday activities.
Benefits of ZEISS MyoActive for Children
1. Spectacle-Based Myopia Management
Children can receive myopia management through spectacles rather than contact lenses.
2. No Contact Lens Handling
There is no need for lens insertion, removal or contact lens cleaning.
This may appeal to parents of younger children who are not ready for contact lenses.
3. New M.O.V.E. Technology
MyoActive introduces non-repetitive optical structures designed to create varying myopic-defocus signals.
4. Promising Clinical Findings
ZEISS reports significant reductions in refractive progression and axial elongation compared with conventional single-vision spectacles.
5. Designed for Everyday Wear
MyoActive combines prescribed vision correction with specialised optical treatment structures.
6. Can Be Monitored Through Ocular Biometry
Prescription and axial-length measurements can help evaluate whether the child’s myopia-management plan is producing the intended response.
Important Considerations Before Choosing ZEISS MyoActive
It does not cure myopia. The objective is to slow progression.
It does not guarantee zero progression. Individual outcomes vary.
Consistent wear matters. The intended optical treatment is delivered while the spectacles are being worn.
Professional fitting is important. Appropriate frame selection, centration and positioning support comfortable use.
Adaptation may be necessary. Some children may need time to become accustomed to the specialised treatment zones.
Longer-term research is still developing. Additional follow-up and independent publication will strengthen the evidence base.
Malaysian specifications must be confirmed. Approved age indications, prescription ranges and final product options may differ between markets.
How Does MyoActive Compare With Other Myopia-Control Spectacle Lenses?
Several manufacturers have developed specialised spectacle lenses for childhood myopia management.
| Lens | Technology | Main optical approach |
|---|---|---|
| ZEISS MyoActive | M.O.V.E. | Dynamic, spatially varying myopic defocus |
| HOYA MiYOSMART | D.I.M.S. | Defocus Incorporated Multiple Segments |
| Essilor Stellest | H.A.L.T. | Highly Aspherical Lenslet Target |
| VisionXlab H.O.R.I. | Hexagonal optical design | Hexagonal lenslet treatment pattern |
All these technologies aim to help slow childhood myopia progression.
However, their optical designs and clinical research programmes differ.
Effectiveness percentages from separate studies should not be directly ranked as though they came from one head-to-head trial.
The most appropriate option depends on the child’s prescription, age, axial length, progression and clinical needs.
ZEISS MyoActive vs Ortho-K, Soft Contact Lenses and Atropine
Spectacle lenses are one of several approaches to childhood myopia management.
| Treatment | When used | Main consideration |
|---|---|---|
| ZEISS MyoActive | Daytime spectacle wear | No contact lens handling |
| Orthokeratology | Overnight contact lens wear | Requires careful hygiene and appropriate fitting |
| Soft myopia-management contact lenses | Daytime contact lens wear | Requires contact lens handling |
| Low-dose atropine | As medically prescribed | Requires medical prescribing and monitoring |
No single treatment is suitable for every child.
Some families prefer spectacles because they are familiar and convenient.
Others may benefit from orthokeratology, soft myopia-management contact lenses or medical co-management.
The appropriate approach should be based on an individual clinical assessment.
Why Malaya Optical Measures Axial Length, Not Just Prescription
At Malaya Optical, myopia management involves more than updating a child’s spectacle power.
Our optometrists use ocular biometry, including the ARK Biometer Combo, to monitor axial length in our myopia-management patients.
Axial length measures the eye from front to back.
Because excessive axial elongation is an important factor in childhood myopia progression, monitoring this measurement helps us understand how the eye is growing.
What We Monitor
| Measurement | Why it matters |
|---|---|
| Refractive prescription | Tracks changes in short-sightedness |
| Axial length | Measures eye growth |
| Progression rate | Helps identify how quickly myopia is changing |
| Baseline measurements | Provides a reference for future reviews |
| Treatment response | Helps evaluate whether management is having the intended effect |
| Wearing habits | Helps interpret adherence and outcomes |
Why Eye Growth Matters
Imagine two children with the same spectacle prescription of −2.00D.
Both begin myopia management.
After six months, their prescriptions remain similar.
However, one child’s axial length has increased more than the other’s.
If we only check spectacle power, we may miss an important difference in their eye-growth patterns.
This is why axial-length monitoring provides valuable information alongside refraction.
At Malaya Optical, we measure eye growth to help guide myopia-management decisions, rather than relying on spectacle power alone.
How Often Should Children Be Reviewed?
Myopia management is an ongoing process.
A baseline examination should be completed before treatment begins.
Depending on the child’s age, progression and clinical needs, follow-up appointments may be scheduled approximately every three to six months, or at another interval recommended by the optometrist.
During follow-up, our optometrists can evaluate prescription changes, axial length, progression rate, spectacle fit, wearing habits and visual comfort.
If progression remains faster than expected, the optometrist may discuss whether adjustments to the management plan are appropriate.
The goal is to use clinical measurements to guide treatment decisions.
Who May Be Suitable for ZEISS MyoActive?
MyoActive is designed for childhood myopia management.
The clinical research included children aged 7–13 years with prescriptions between approximately −0.75D and −5.00D.
However, these were study inclusion criteria rather than universal prescribing limits.
Suitability should be determined through a comprehensive eye examination and the approved Malaysian product specifications.
Important considerations include:
- Age
- Current prescription
- Rate of progression
- Axial length
- Family history
- Astigmatism
- Previous myopia-management treatment
- Lifestyle and visual needs
- Ability to wear spectacles consistently
Myopia Management for Malaysian Schoolchildren
Children in Malaysia often spend long periods on near-vision activities.
School lessons, homework, tuition, digital learning and recreational screen use can contribute to extended close-up visual demands.
Busy urban routines in Kuala Lumpur, Petaling Jaya, Subang Jaya and Puchong may also limit opportunities for outdoor activity.
However, myopia is influenced by several factors, including genetics, age and environmental exposure.
Screen use alone should not be described as the sole cause.
What Parents Can Do
Encourage regular outdoor activity when practical and safe.
Provide breaks during prolonged near work.
Encourage comfortable reading distances.
Ensure suitable lighting during study.
Schedule regular eye examinations.
Follow the recommended wearing and review schedule for prescribed myopia-management treatments.
These habits support healthy visual routines but do not replace appropriate clinical management when a child has progressing myopia.
Why Early Detection Matters
Children do not always recognise that their distance vision is becoming blurry.
Parents or teachers may notice squinting, difficulty seeing the classroom board, moving closer to screens or frequent prescription changes.
Malaya Optical has participated in eye-screening programmes at both international and government schools.
These experiences reinforce the importance of identifying possible vision problems early.
School screening can help identify children who need further assessment, but it does not replace a comprehensive eye examination.
Frequently Asked Questions About ZEISS MyoActive
What is ZEISS MyoActive?
ZEISS MyoActive is a new-generation myopia-management spectacle lens using M.O.V.E. technology to create varying optical-defocus signals intended to slow childhood myopia progression.
What does M.O.V.E. stand for?
M.O.V.E. stands for Micro Optical Variable Elements.
What is Dynamic Signal Theory?
Dynamic Signal Theory is ZEISS’s approach to creating varying myopic-defocus signals intended to reduce adaptation to repetitive optical stimulation.
How effective is ZEISS MyoActive?
ZEISS reports 0.60D less refractive progression and 0.22 mm less axial elongation over one year compared with conventional single-vision spectacles in its clinical trial.
Does MyoActive stop myopia completely?
No. MyoActive aims to slow progression, but individual outcomes vary.
Can MyoActive cure myopia?
No. It corrects existing short-sightedness and is designed to help manage further progression.
Is MyoActive better than MiYOSMART or Stellest?
There is insufficient direct head-to-head evidence to conclude that MyoActive is superior to these alternatives for every child.
Is MyoActive suitable for young children?
It may be appropriate for some children with progressing myopia, depending on their clinical assessment and the approved product indications.
Does my child need to wear MyoActive every day?
Consistent wear is important. Follow the wearing schedule recommended by the child’s optometrist.
Does my child still need regular eye examinations?
Yes. Ongoing monitoring of prescription, axial length, spectacle fit and treatment response remains important.
Why is axial length important?
Axial length measures eye growth. Monitoring changes helps assess myopia progression and evaluate treatment response.
Is ZEISS MyoActive available in Malaysia?
ZEISS introduced MyoActive internationally in October 2026. Malaysian retail availability, approved indications and launch timing should be confirmed locally.
Will Malaya Optical carry ZEISS MyoActive?
ZEISS MyoActive is coming soon to Malaya Optical, with planned availability at all four branches.
Parents can enquire about its upcoming availability while arranging a comprehensive myopia assessment.
ZEISS MyoActive Is Coming Soon to Malaya Optical Malaysia
Malaya Optical has been caring for the visual needs of Malaysian families since 1957.
Our approach to childhood myopia management combines comprehensive eye examinations, clinical measurements, suitable optical technologies and ongoing monitoring.
With a team of optometrists and access to ocular biometry, we focus on understanding each child’s progression rather than simply updating their prescription.
ZEISS MyoActive will soon join our myopia-management spectacle lens options.
Planned availability includes:
- Malaya Optical Jalan Imbi — Kuala Lumpur
- Malaya Optical Damansara Uptown — Petaling Jaya
- Malaya Optical SS15 — Subang Jaya
- Malaya Optical Bandar Puteri — Puchong
Book a Children’s Myopia Assessment
If your child’s spectacle prescription continues to increase, a comprehensive assessment can help determine the next step.
Our optometrists can evaluate prescription changes, axial length, progression history and visual needs before discussing appropriate management options.
Book your child’s myopia assessment: https://book.malayaoptical.com
Interested in ZEISS MyoActive?
Although MyoActive is not yet available at our branches, parents are welcome to contact Malaya Optical to enquire about its upcoming availability.
Our team can also discuss currently available myopia-management options while you await the new technology.
Clear vision matters today. Managing myopia progression matters for the years ahead.
Disclaimer: This article provides general educational information and does not replace an individual eye examination or professional clinical advice. Myopia-management outcomes vary between children. ZEISS MyoActive availability, approved indications and specifications in Malaysia should be confirmed before prescribing.
Research References
- ZEISS Vision Care. ZEISS Introduces MyoActive. 1 October 2026.
https://www.zeiss.com/vision-care/en/newsroom/news/2026/zeiss-introduces-myoactive.html - ZEISS Myopia Insights Hub. Dynamic Signal Variation: Enhancing Myopia Control by Reducing Adaptation. 6 October 2026.
https://www.zeiss.com/myopia/en/articles–insights/enhancing-myopia-control-by-reducing-adaptation.html - ZEISS Myopia Insights Hub. Novel Spectacle Lens Designs for Myopia Management: High Efficacy With ZEISS MyoActive Lenses. 22 May 2026.
https://www.zeiss.com/myopia/en/articles–insights/high-efficacy-with-zeiss-myoactive-lenses.html - ZEISS Vision Care. ZEISS to Present New Clinical Study Results on Novel Myopia Management Lens ZEISS MyoActive at ARVO 2026. 5 May 2026.
https://www.zeiss.com/vision-care/en/newsroom/news/2026/zeiss-to-present-new-clinical-study-results-at-arvo-2026-.html - ClinicalTrials.gov. Clinical Study NCT06563700.
https://clinicaltrials.gov/study/NCT06563700